Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of GLK-221 Ophthalmic Solution in Subjects With Keratoconus
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
Multi-center, parallel-group, placebo-controlled trial designed to assess the safety and efficacy of twice-daily topically administered GLK-221 Ophthalmic Solution in subjects with keratoconus.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 55
Healthy Volunteers: f
View:
• Be ≥ 18 and ≤ 55 years of age
• Diagnosis of keratoconus in the study eye
Locations
United States
Ohio
Glaukos Clinical Study Site
RECRUITING
Westerville
Contact Information
Primary
Study Manager
ClinicalResearch@Glaukos.com
949-739-8749
Time Frame
Start Date: 2025-12-23
Estimated Completion Date: 2027-04
Participants
Target number of participants: 100
Treatments
Experimental: GLK-221 Ophthalmic Solution
GLK-221 Ophthalmic Solution administered topically twice daily to both eyes
Placebo_comparator: Placebo
Placebo Ophthalmic Solution administered topically twice daily to both eyes
Related Therapeutic Areas
Sponsors
Leads: Glaukos Corporation